^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Imunace (teceleukin)

i
Other names: BG 8301, RO 23 6019 , S 6820, Bioleukin, Bioleukin IL-2
Associations
Company:
Shionogi
Drug class:
IL-2 stimulant
Related drugs:
Associations
3ms
NCI-2018-01509: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P2, N=60, Terminated, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Aug 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Aug 2024; Lack of Efficacy
Trial completion date • Trial termination • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
|
cyclophosphamide • fludarabine IV • Imunace (teceleukin)
9ms
Trial primary completion date • Metastases
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
11ms
Enrollment change • Trial primary completion date
|
CD8 (cluster of differentiation 8) • CD28 (CD28 Molecule) • CD27 (CD27 Molecule)
|
CD8 expression • CD28 expression
|
cyclophosphamide • fludarabine IV • Imunace (teceleukin)
12ms
Enrollment open
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
12ms
New P2 trial
|
cyclophosphamide • fludarabine IV • Amtagvi (lifileucel) • Imunace (teceleukin)
4years
Clinical • Enrollment open • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
over4years
Clinical • Trial suspension • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
almost5years
Clinical • Enrollment open • CAR T-Cell Therapy
|
BRAF (B-raf proto-oncogene) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL2 (Interleukin 2)
|
BRAF mutation • BRAF V600
|
fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous